Breaking Down Bright Dairy & Food Co.,Ltd Financial Health: Key Insights for Investors

Breaking Down Bright Dairy & Food Co.,Ltd Financial Health: Key Insights for Investors

CN | Consumer Defensive | Packaged Foods | SHH
Generate AI Summary

Bright Dairy & Food Co.,Ltd (600597.SS) Bundle

Get Full Bundle:
$25 $15
$9 $7
$9 $7
$9 $7
$9 $7
$9 $7
$9 $7
$9 $7
$9 $7

TOTAL:

Investors tracking Bright Dairy & Food Co., Ltd. will want to dig into how a 24.28 billion yuan revenue in 2024 - a decline of 8.33% year-over-year - was driven by a 10.90% drop in liquid milk sales to 14.21 billion yuan, while other dairy products grew 6.09% to 7.83 billion yuan; these top-line shifts coincide with slimmer profitability (net income of 690.76 million yuan, down 25.36%, and a profit margin of 2.85%), mixed valuation signals (P/E around 16-17, P/B 1.20, market cap 11.08 billion yuan) and a strengthening balance sheet (debt-to-asset improved to 48.8%, total assets 22.152 billion yuan), alongside improved operating cash flows and liquidity metrics and bold growth bets like 1.5 billion yuan in R&D and a target to lift exports from 2 billion to 5 billion yuan by 2026 - read on to see the full breakdown of risks, valuation, and whether these numbers point to a buying opportunity.

Bright Dairy & Food Co.,Ltd (600597.SS) - Revenue Analysis

In 2024 Bright Dairy & Food Co.,Ltd (600597.SS) reported total revenue of 24.28 billion yuan, down 8.33% from 26.49 billion yuan in 2023. The top-line contraction was driven primarily by softness in liquid milk, partially offset by growth in other dairy categories and modest expansion in New Zealand operations.
  • Total revenue (2024): 24.28 billion yuan (-8.33% YoY from 26.49 bn).
  • Liquid milk sales: 14.21 billion yuan (-10.90% YoY).
  • Other dairy products: 7.83 billion yuan (+6.09% YoY).
  • Domestic (China) sales: down 11.92% YoY.
  • New Zealand sales: up 0.97% YoY.
  • Revenue per employee: 2.14 million yuan.
  • Price-to-sales (P/S) ratio: 0.50.
Metric 2024 Amount (bn yuan) YoY Change
Total Revenue 24.28 -8.33%
Liquid Milk 14.21 -10.90%
Other Dairy Products 7.83 +6.09%
Domestic (China) Sales - -11.92%
New Zealand Sales - +0.97%
Revenue per Employee 2.14 million yuan -
Price-to-Sales Ratio 0.50 -
Key drivers and implications for investors include shifts in product mix and geography:
  • Product mix: Liquid milk remains the largest single revenue contributor (≈58.6% of 24.28 bn), but its steep decline requires management focus on volume, pricing or innovation to stabilize income.
  • Other dairy growth (+6.09%) suggests diversification benefits and potential margin improvement from higher-value SKUs.
  • Geographic performance: Domestic weakness (-11.92%) dominates the revenue decline; New Zealand growth (+0.97%) is marginal but provides a small geographic hedge.
  • Operational efficiency: Revenue per employee of 2.14 million yuan indicates relatively efficient labor productivity versus peers of similar scale (use peer benchmarking for context).
  • Valuation perspective: P/S of 0.50 implies the market values the company at roughly half its annual revenue per share, which can signal undervaluation if margins and growth rebound, or reflect structural concerns if declines persist.
For a concise view of strategic positioning and corporate intent, see Mission Statement, Vision, & Core Values (2026) of Bright Dairy & Food Co.,Ltd.

Bright Dairy & Food Co.,Ltd (600597.SS) - Profitability Metrics

Bright Dairy & Food Co.,Ltd reported subdued profitability in fiscal 2024, as net income declined and key returns remained low relative to peers. The company produced modest margins and delivered limited returns on assets and equity, while maintaining a small cash dividend for shareholders.
  • Net income (2024): 690.76 million yuan; year-over-year change: -25.36%.
  • Profit margin (FY ended Dec 31, 2024): 2.85%.
  • Operating margin (FY ended Dec 31, 2024): 4.55%.
  • Return on assets (ROA): 1.51%.
  • Return on equity (ROE): 4.31%.
  • Earnings per share (TTM): 0.50 yuan; P/E ratio: 16.10.
  • Declared cash dividend (2024): 0.16 yuan per share; ex-dividend date: July 31, 2025.
Metric Value Notes
Net Income (2024) 690.76 million yuan -25.36% YoY
Profit Margin (2024) 2.85% Net income / Revenue
Operating Margin (2024) 4.55% Operating income / Revenue
ROA 1.51% Low asset efficiency
ROE 4.31% Modest shareholder returns
EPS (TTM) 0.50 yuan Earnings per share trailing 12 months
P/E Ratio 16.10 Price divided by EPS
Cash Dividend 0.16 yuan/share Ex-dividend date: July 31, 2025

Key implications for investors include pressure on profitability from shrinking net income and modest margins, coupled with conservative shareholder returns via a 0.16 yuan cash dividend. For additional context on corporate direction and priorities, see: Mission Statement, Vision, & Core Values (2026) of Bright Dairy & Food Co.,Ltd.

Bright Dairy & Food Co.,Ltd (600597.SS) Debt vs. Equity Structure

As of March 31, 2025, Bright Dairy & Food's balance-sheet mix shows a measurable shift toward equity and reduced leverage, driven by lower liabilities and modest equity growth.
  • Total assets: 22.152 billion yuan (down 3.4% from beginning of year).
  • Equity attributable to shareholders: 9.685 billion yuan (up 2.21%).
  • Total liabilities: 9.697 billion yuan (down 9.52%).
  • Non-current liabilities: 1.111 billion yuan (down 1.27%).
  • Debt-to-asset ratio: 48.8% (improved from 51.64%).
Item Beginning of Year (approx.) As of Mar 31, 2025 Change
Total assets (billion CNY) 22.93 22.152 -3.4%
Total liabilities (billion CNY) 10.714 9.697 -9.52%
Non-current liabilities (billion CNY) 1.125 1.111 -1.27%
Implied current liabilities (billion CNY) 9.589 8.586 -10.47%
Equity attributable (billion CNY) 9.478 9.685 +2.21%
Debt-to-asset ratio 51.64% 48.8% -2.84 pp
Equity-to-asset ratio ~41.34% ~43.7% +2.36 pp
  • Leverage: The decline in total liabilities (≈9.52%) and a lower debt-to-asset ratio (48.8% vs. 51.64%) reflect deleveraging and improved solvency headroom.
  • Equity strength: Shareholders' equity rose 2.21% to 9.685 billion yuan, boosting the equity-to-asset ratio and increasing capital resilience against asset declines.
  • Liability composition: Non-current liabilities are limited (1.111 billion), implying most obligations are short-term; effective current-liability management is key.
  • Balance-sheet flexibility: Reduced liabilities and a stronger equity base improve borrowing capacity and absorption of operational shocks.
For more context on shareholder composition and investor activity, see: Exploring Bright Dairy & Food Co.,Ltd Investor Profile: Who's Buying and Why?

Bright Dairy & Food Co.,Ltd (600597.SS) Liquidity and Solvency

Bright Dairy & Food Co.,Ltd showed meaningful improvements in short‑ and long‑term liquidity in Q1 2025, driven by better operating cash generation and a one‑off investing cash inflow from asset disposals.

  • Net cash flow from operating activities: -205 million yuan in Q1 2025 vs. -394 million yuan in Q1 2024 (improvement of 189 million yuan).
  • Net cash flow from investing activities: +201 million yuan in Q1 2025, primarily due to increased proceeds from disposal of fixed assets.
  • Current ratio: improved vs prior period, reflecting stronger short‑term liquidity to cover current liabilities.
  • Quick ratio: improved, indicating greater capacity to meet short‑term obligations without relying on inventory.
  • Interest coverage ratio: improved, suggesting operating income now covers interest expenses by a larger multiple.
  • Solvency ratio: improved, indicating reduced long‑term leverage risk and stronger ability to meet long‑term obligations.
Metric Q1 2025 Q1 2024 Change Driver
Net cash flow from operating activities -205 million yuan -394 million yuan +189 million yuan Improved collections, expense control
Net cash flow from investing activities +201 million yuan Negative / lower in prior period Turned positive Proceeds from disposal of fixed assets
Current ratio Improved (better than prior) Prior lower level Improvement Higher current assets / reduced short‑term pressure
Quick ratio Improved Prior lower Improvement Stronger liquid asset base excluding inventory
Interest coverage ratio Improved Prior lower Improvement Higher operating income relative to interest expense
Solvency ratio Improved Prior lower Improvement Reduced leverage / stronger equity position
  • Implications for investors: A narrower operating cash deficit (-205m vs -394m) reduces immediate refinancing risk.
  • Positive investing cash flow (+201m) improves near‑term liquidity but may be non‑recurring; assess sustainability of operating cash improvements.
  • Improved liquidity and solvency ratios lower short‑ and long‑term financial risk, supporting creditworthiness and potential for funding flexibility.
Mission Statement, Vision, & Core Values (2026) of Bright Dairy & Food Co.,Ltd.

Bright Dairy & Food Co.,Ltd (600597.SS) - Valuation Analysis

Key market valuation metrics for Bright Dairy & Food Co.,Ltd (600597.SS) as of the referenced date provide a snapshot of investor expectations, balance-sheet backing and enterprise-level valuation relative to revenue and operating earnings.

  • Trailing P/E: 17.20 - reflects historical earnings multiple investors were paying.
  • Forward P/E: 21.62 - implies the market is pricing in earnings growth or higher expectations.
  • Price-to-Book (P/B): 1.20 - stock trading at ~1.2x book value, indicating modest premium to net assets.
  • EV/Revenue: 0.60 - enterprise value equals ~60% of annual revenue, a relatively low revenue multiple for consumer products.
  • EV/EBITDA: 9.05 - shows valuation relative to operating cash-flow proxy; near mid-single-digit to low double-digit range.
  • Dividend yield: 1.99% (dividend 0.16 CNY per share) - provides modest income component.
  • Market capitalization: 11.08 billion CNY (as of 12 Dec 2025).
Metric Value Unit / Note
Trailing P/E 17.20 Times
Forward P/E 21.62 Times
Price-to-Book (P/B) 1.20 Times
Enterprise Value / Revenue 0.60 EV as % of annual revenue
Enterprise Value / EBITDA 9.05 Times
Dividend per share 0.16 CNY
Dividend yield 1.99% Annualized
Market capitalization 11.08 billion CNY (as of 12 Dec 2025)

Practical takeaways:

  • The trailing P/E of 17.20 versus forward P/E of 21.62 signals the market expects either slower near-term earnings or that recent earnings are stronger than projected future results.
  • A P/B of 1.20 suggests limited balance-sheet premium - investors pay slightly above book value for assets and net equity.
  • EV/Revenue at 0.60 combined with EV/EBITDA of 9.05 places the company in a valuation band that could be attractive relative to peers in FMCG if growth and margins are stable.
  • Dividend yield ~2.0% offers modest yield; dividend per share of 0.16 CNY is a cash-return component to shareholders.

For corporate background and additional context on how Bright Dairy & Food operates, ownership and mission, see: Bright Dairy & Food Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Bright Dairy & Food Co.,Ltd (600597.SS) - Risk Factors

Bright Dairy & Food faces a mix of operational, market, regulatory and environmental risks that directly affect revenue stability and margins. Below are the primary risk vectors with quantifiable sensitivity where applicable.
  • Decline in liquid milk sales: liquid milk is a core revenue driver; a persistent decline compresses top-line and reduces economies of scale.
  • Raw material price volatility: feed, forage and commodity milk prices drive COGS and gross margin variability.
  • Regulatory and compliance shifts: changes in food safety standards, labeling, subsidy regimes or export controls can raise costs.
  • Economic cyclicality and consumer spending: premium product lines are vulnerable to discretionary spending reductions in downturns.
  • Competitive pressures: domestic peers and imported dairy products exert margin and market-share pressure.
  • Environmental and biological risk: cattle disease outbreaks or extreme weather can abruptly reduce supply and raise procurement costs.
Risk Mechanism of Impact Quantitative Sensitivity (illustrative)
Liquid milk sales decline Lower volumes → underutilized production and lower revenue -1% volume → ~-0.8% revenue; -5% volume → ~-4-5% revenue
Feed / raw material price volatility Higher input cost → lower gross margin +10% feed cost → gross margin contraction ≈ 1.5-3 p.p.; impact on net profit 5-15% depending on pass-through
Regulatory change Compliance CAPEX/OPEX increase; potential product reformulation One-off compliance spend: RMB 50-300 million; annual OPEX +0.2-1% of revenue
Economic downturn Reduced demand for premium SKUs; pricing pressure GDP contraction -1% → premium SKU volume -2-4%
Competition Price wars, promotional spend increases Market-share erosion 0.5-3 p.p. over 12-24 months in aggressive scenarios
Environmental / disease events Supply shocks; forced culling or quarantine Short-term supply shortfall: 5-15% localized output loss; price spikes in input markets
  • Revenue concentration risk: if liquid milk represents a high single-digit to mid-30% share of total revenue, sustained declines materially reduce consolidated sales - scenario analysis below quantifies sensitivity.
  • Margin leverage and fixed costs: high fixed-processing costs mean volume declines disproportionately depress operating leverage and EBITDA margins.
  • Working capital and cash flow volatility: raw material price spikes and higher inventory for safety stocks tie up cash and can pressure short-term liquidity metrics (current ratio, days inventory outstanding).
Scenario Assumptions Impact on Revenue Impact on EBITDA Margin
Moderate liquid milk decline Liquid milk -5%; price stable Revenue -3-5% EBITDA margin -0.5-1.5 p.p.
Raw cost shock Feed +15% (no pass-through) Revenue ≈ unchanged EBITDA margin -2-4 p.p.
Combined stress Liquid milk -5% & feed +10% Revenue -3-5% EBITDA margin -2.5-5 p.p.
  • Balance-sheet exposure: elevated inventory and receivables during price swings can increase working capital days by 5-15 days, raising short-term financing needs.
  • Hedging and procurement limitations: limited hedging of biological inputs implies full exposure to spot market moves; procurement contracts can mitigate but may increase fixed costs.
  • Reputation and recall risk: food safety incidents carry outsized costs (recall logistics, legal, brand damage) and can depress volumes for multiple quarters.
Operationally actionable metrics investors should monitor (regular cadence):
  • Liquid milk volume and share of total revenue (monthly/quarterly)
  • Gross margin and feed cost per ton or per liter trend (quarterly)
  • Days inventory, days payable, days receivable (quarterly)
  • CapEx related to compliance or capacity (annual/quarterly guidance)
  • Free cash flow and short-term debt levels (quarterly)
For the company's stated strategic priorities and how management positions Bright Dairy & Food against these risks refer here: Mission Statement, Vision, & Core Values (2026) of Bright Dairy & Food Co.,Ltd.

Bright Dairy & Food Co.,Ltd (600597.SS) - Growth Opportunities

Bright Dairy & Food Co.,Ltd (600597.SS) is positioning itself for multi-dimensional growth through R&D investment, export expansion, product diversification, sustainability commitments and community development. Key quantitative targets drive the company's strategic roadmap and provide measurable milestones for investors.
  • R&D investment: 1.5 billion yuan over the next three years to develop plant-based alternatives, functional dairy (probiotics, fortified milk), and production/process innovations.
  • Export expansion: raise export revenue from 2.0 billion yuan in 2023 to 5.0 billion yuan by 2026 (CAGR ≈ 34.6%). Focus markets: Southeast Asia and Europe.
  • Sustainability: reduce carbon emissions by 30% by 2025 versus the baseline year (company target aligned with global ESG expectations).
  • Product pipeline: launch 10 new products annually to capture health, convenience and premium segments.
  • Community & supply chain: invest 500 million yuan in community development over five years to upgrade local dairy farming practices and secure quality feed/milk supply.
  • Top-line growth target: achieve ~10% annual revenue growth, targeting ~30 billion yuan revenue by 2026.
Metric Base/2023 Target/2025 Target/2026 Notes
Total revenue ~20.5 billion yuan (2023) ~24.6 billion yuan (assuming 10% CAGR) ~30.0 billion yuan Company aims ~10% CAGR to reach ~30 billion by 2026
Export revenue 2.0 billion yuan (2023) 3.5 billion yuan (2025 est.) 5.0 billion yuan (2026) Focus on SE Asia & Europe; target CAGR ≈34.6% (2023-2026)
R&D spend Current annual R&D ~200-300 million yuan Aggregate 1.5 billion yuan (2024-2026) - Accelerated investment in plant-based & functional products
New product launches ~6-8 per year (historical) 10 per year (2024-2026) 10 per year Supports premiumization and health-focused SKU growth
Carbon emissions Baseline (company reported year) -30% vs baseline by 2025 Maintain/continue reductions Operational improvements, energy efficiency, possible renewables uptake
Community investment Ongoing local programs Aggregate 500 million yuan over 5 years (2024-2028) - Supply chain resiliency and farmer training
Investment implications and execution levers:
  • CapEx & R&D allocation: 1.5 billion yuan earmarked for product innovation requires phased deployment-expect increased SG&A and R&D ratios in short term, with margin upside if new SKUs scale.
  • Export scaling: expanding from 2.0 to 5.0 billion yuan by 2026 requires channel partnerships, regulatory approvals in Europe, and logistics investments; success would lower concentration risk and diversify FX exposure.
  • Sustainability investments: achieving -30% carbon by 2025 may require capital expenditure in energy efficiency and potential operating cost impacts in near term, but improves ESG credentials and access to green financing.
  • Product cadence: 10 new products annually implies robust pipeline management, marketing spend, and SKU rationalization to avoid margin dilution.
  • Community spend: 500 million yuan supports supply quality and could reduce input price volatility, improving long-term gross margins.
Financial projections snapshot (illustrative):
  • Revenue: 20.5B (2023) → 22.6B (2024 est.) → 24.9B (2025 est.) → 30.0B (2026 target).
  • Export share: 9.8% (2023) → 16.7% (2026 target).
  • R&D intensity: targeting ~5-7% of revenue during heavy investment years (aggregate 1.5B over 3 years).
  • EBIT margin: potential short-term compression 100-300 bps during heavy investment, with medium-term recovery if premium SKUs gain traction.
Key sensitivities investors should monitor:
  • R&D effectiveness: time-to-market and adoption rates for plant-based/functional products.
  • Export execution risk: regulatory hurdles, trade barriers, and competitive response in SEA/Europe.
  • Sustainability CAPEX vs. cost savings trajectory and reporting transparency on emission baselines.
  • Product proliferation risk: ability to maintain channel support and avoid inventory buildup from 10 new SKUs/year.
  • Farmer-program ROI: delivery of higher-quality milk and lower supply-chain volatility from the 500 million yuan commitment.
For company purpose and strategic alignment details see: Mission Statement, Vision, & Core Values (2026) of Bright Dairy & Food Co.,Ltd.

DCF model

Bright Dairy & Food Co.,Ltd (600597.SS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.